Immune-related adverse events with bispecific T-cell engager therapy targeting B-cell maturation antigen

Haematologica. 2024 Jan 1;109(1):357-361. doi: 10.3324/haematol.2023.282919.
No abstract available

MeSH terms

  • Antibodies, Bispecific* / adverse effects
  • B-Cell Maturation Antigen*
  • Humans
  • T-Lymphocytes

Substances

  • B-Cell Maturation Antigen
  • Antibodies, Bispecific